Interactive modules by Olga Goodman, MD.Copyright protected · Read termsClose terms

All RheumaView™ interactive modules, quizzes and educational cases are original works developed by Olga Goodman, MD.

Without the author’s prior written permission, you may not copy or republish these modules or their components; extract, reuse or modify their original software code (“engines”); or use that code to build your own modules, quizzes or other products.

You may not claim these works as your own or remove or replace the author’s name or copyright notices. When quoting material, credit Olga Goodman, MD, identify the source and include a direct link to the original.

Free or public access is provided for learning and does not grant permission to copy, adapt or redistribute the materials. Unauthorized use of protected material may constitute copyright infringement. Exceptions and limitations provided by applicable law remain unaffected.

Sharing direct links to the modules is welcome.

© 2026 Olga Goodman, MD. All rights reserved.

Skip to article
Contents · Peripheral SpA
Chapter 5 · Diagnosis and phenotyping

Diagnosis, Classification and the 2025 ASAS–SPARTAN Revised Axial Criteria

Use peripheral and axial classification in their intended populations, with explicit criteria versions and a separate clinical diagnostic judgment.

Open accessEvidence reviewed:
On this page

Classification is a research decision; diagnosis is a clinical judgment

Classification criteria assemble sufficiently comparable participants for research. Clinical diagnosis asks what best explains an individual patient’s findings and what must be done next. The two processes share evidence but have different purposes and tolerances for error. A criteria-positive result does not remove competing diagnoses, and a criteria-negative result does not automatically exclude clinically credible disease.

This matters especially in peripheral SpA, where the entry manifestation may itself be uncertain. Tenderness at a heel is not automatically inflammatory enthesitis. A reported swollen finger is not necessarily dactylitis. Classification performed before confirming the nature of the manifestation can convert a weak premise into an apparently authoritative conclusion.

The 2011 peripheral framework

The ASAS peripheral criteria start with arthritis, enthesitis or dactylitis. Classification then uses either at least one of psoriasis, IBD, preceding infection, HLA-B27, uveitis or sacroiliitis on imaging; or at least two of arthritis, enthesitis, dactylitis, previous inflammatory back pain or family history of SpA. Apply the published definitions rather than counting loosely related symptoms. [1]

The framework was developed in newly referred patients with peripheral manifestations, generally beginning before age 45. That derivation context is not a bedside rule that peripheral SpA becomes impossible after a birthday. It is a reason to scrutinize transportability, competing diagnoses and the meaning of test performance in a different clinical population.

The historical 2009 axial framework

The 2009 axial criteria address chronic back pain beginning before age 45. They allow classification through sacroiliitis on imaging plus a SpA feature, or through HLA-B27 plus additional SpA features. [2] Those entry conditions are central. Applying an axial algorithm to a person without an axial presentation does not establish the cause of an ankle effusion.

Likewise, “non-radiographic” is not a synonym for undifferentiated peripheral disease. It refers to an axial classification context. A patient whose historical uSpA diagnosis was principally axial should be reassessed within the appropriate axial pathway, while the current peripheral manifestations are recorded in parallel.

What changed in the 2025 ASAS–SPARTAN work

The revised axial criteria were presented in ACR Convergence 2025 abstract 0854 on October 27, 2025. The CLASSIC development and validation work pursued higher specificity and reported revised weighted criteria with greater emphasis on imaging. In the validation results reported in the abstract, sensitivity was 79.5% and specificity 90.4%. [3] These are study-level performance estimates, not the probability that a particular patient has or lacks axSpA.

Publication status on October 6, 2026: the original development evidence cited here is a congress abstract. A 2026 peer-reviewed letter evaluates the proposed criteria in an acute anterior uveitis cohort; that is additional validation work, not the original full criteria-development report. [4] The criteria name remains 2025 ASAS–SPARTAN revised axial criteria. Later analyses do not change that version label.

The central clinical consequence is to separate a more specific research gate from the full diagnostic assessment. Stricter classification can change who enters a study without determining that excluded patients have no inflammatory disease. The converse remains equally important: imaging must be read in context, not accepted uncritically because a revised framework emphasizes it.

Imaging specificity is a clinical problem too

Sacroiliac bone-marrow edema is not unique to axSpA. A primary MRI study found findings meeting an ASAS imaging definition in some healthy participants and people exposed to mechanical or postpartum stress. [5] A radiology phrase must therefore be interpreted alongside lesion distribution, structural findings, image quality, symptoms and competing explanations. Do not transform “edema present” directly into “inflammatory axial disease established.”

When an imaging report and clinical picture disagree, obtain clarification or expert review of the actual study. Repeating scans indiscriminately is less useful than identifying the unresolved question: artifact, mechanical stress, infection, structural lesion interpretation, or insufficiently characterized symptoms. A negative scan also has to be interpreted in its temporal and treatment context.

How to document a criteria result responsibly

FieldWhat to record
Clinical diagnosisWorking disease explanation, confidence, phenotype and alternatives
Classification frameworkExact name and year; peripheral or axial population
Entry conditionHow the required manifestation or symptom history was established
Supporting itemsConfirmed evidence, its source and date; uncertain items kept separate
ImagingModality, site, date, relevant interpretation and review where needed
MeaningResearch eligibility or descriptive classification, without substituting for diagnosis
ReassessmentWhat new finding would change the judgment or route

Common errors and their consequences

Counting an uncertain manifestation as certain: an equivocal skin rash, generic family “arthritis,” or undocumented red eye should not silently become a confirmed item. Clarify the source. Double-counting clinical impressions: several descriptions of the same uncertain symptom do not create independent evidence. Using treatment response as proof: analgesic and anti-inflammatory responses occur in multiple conditions.

Using classification to deny the differential: criteria-positive SpA does not protect the patient from infection, gout or a second inflammatory disease. Using a negative result to end evaluation: a framework optimized for research specificity can miss some clinically diagnosed disease. Applying the wrong population: axial, peripheral and PsA criteria should not be mixed into an improvised score.

Version control for educational tools

An educational classification tool should state exactly which criteria it implements, retain the original entry requirements and display publication status when discussing new versions. Its output should explain the limited meaning of a classification result. Updating a heading without auditing the questions, definitions and branching logic would be misleading.

This chapter links directly to the source reports rather than presenting an unverified reproduction of the new weighted algorithm. For bedside decisions, use the full clinical assessment. For research enrollment, use the protocol-specified version and the original definitions, not a blended recollection of several generations of criteria.

Evidence in context

Source status checked October 6, 2026. Population applicability and publication maturity are separate judgments.

Scrollable evidence table

SourcePopulation and phenotypeDesign and statusApplicabilityClinical implicationImportant limitationLast checked
2011 peripheral criteria [1]Peripheral entry manifestationsDevelopment/validation; peer-reviewedPeripheral classificationKeep the correct entry phenotypeNot diagnostic criteria for an unselected patient2026-10-06
2009 axial criteria [2]Chronic back pain with young onsetDevelopment/validation; peer-reviewedAxial classificationHistorical version must remain identifiedNot transferable wholesale to peripheral disease2026-10-06
2025 ASAS–SPARTAN [3]CLASSIC axial referral cohortDevelopment/validation; congress abstractRevised axial classificationHigher-specificity research frameworkOriginal full development paper not established here2026-10-06
Uveitis validation [4]Acute anterior uveitis cohortPublished letter, July 2026Selected external axial contextShows ongoing validation workNot the original criteria-development report2026-10-06
MRI comparator study [5]Healthy, axial disease, back-pain and stress-exposed groupsCross-sectional; peer-reviewedAxial imaging interpretationEdema alone is not disease-specificSelected groups; small postpartum subgroup2026-10-06

Sources

  1. Rudwaleit et al. ASAS peripheral classification criteria (2011)
  2. Rudwaleit et al. ASAS axial criteria: validation and final selection (2009)
  3. Maksymowych et al. 2025 ASAS–SPARTAN revised axial criteria: ACR abstract 0854
  4. Rai et al. Performance of proposed ASAS/SPARTAN criteria in uveitis: letter (2026)
  5. de Winter et al. Sacroiliac MRI in healthy individuals, runners and postpartum back pain (2018)

Share this page

FacebookLinkedInXWhatsAppTelegram

Topics: Peripheral SpASpondyloarthritis